Gavin Chartier, MD
Interventional Pain Medicine · Vincennes, INNPI 1982679494
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,527 of the $5,637 with a category attached, or 80.3%. 34 manufacturers reported payments, led by Medtronic at 37.7% of the total. Reporting peaked in 2020 at $1,876 and has fallen 80.3% since, to $370 in 2024.
Across 188 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Stimwave Technologies Incorporated$611
- Nevro Corp.$478
- Vertos Medical, Inc.$303
- Eisai Inc.$247
- Lilly USA, LLC$214
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,11020%
- Food & beverage$4,52780%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 60 | $2,127 |
| Stimwave Technologies Incorporated | 10 | $611 |
| Nevro Corp. | 16 | $478 |
| Vertos Medical, Inc. | 6 | $303 |
| Eisai Inc. | 17 | $247 |
| Lilly USA, LLC | 12 | $214 |
| Stryker | 2 | $193 |
| Pfizer | 8 | $132 |
| GRT US Holding, Inc. | 1 | $119 |
| Amgen | 6 | $106 |
| Si-bone, Inc. | 1 | $101 |
| Curonix LLC | 1 | $98 |
| AbbVie(2 entities) | 5 | $93 |
| Teva Pharmaceuticals USA, Inc. | 5 | $77 |
| Biohaven Pharmaceuticals, Inc. | 4 | $72 |
| Boston Scientific | 4 | $69 |
| Upsher-smith Laboratories LLC | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $55 |
| Flowonix Medical Incorporated | 1 | $52 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| MML US, Inc. | 3 | $48 |
| Merck | 2 | $43 |
| Abbott | 2 | $43 |
| Zyla Life Sciences, Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $33 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Bioventus LLC | 1 | $20 |
| Virtus Pharmaceuticals LLC | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Alkermes, Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Spinal Simplicity, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,637 in reported general payments places this provider in the 60th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,015 | $28,454 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 880 | $26,483 |
| MovantikNaloxegol Oxalate | 59 | $25,545 |
| Lidocaine | 116 | $19,955 |
| QuliptaAtogepant | 15 | $16,181 |
| UbrelvyUbrogepant | 13 | $13,107 |
| OxycontinOxycodone Hcl | 16 | $11,584 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,329 |
| Oxycodone Hcl | 230 | $6,639 |
| Diclofenac Sodium | 92 | $6,358 |
| Pregabalin | 174 | $4,945 |
| Gabapentin | 347 | $4,225 |
| Morphine Sulfate ErMorphine Sulfate | 112 | $4,023 |
| Buprenorphine | 14 | $3,548 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $3,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $93 | $29,28828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Vincennes
- Joshua WellingtonCarmel$315K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Scott KimGreenwood$18K
- Edward KowlowitzIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.